Canine Chronic Kidney Disease: Retrospective Study of a 10-Year Period of Clinical Activity

2011 ◽  
pp. 115-118 ◽  
Author(s):  
G. Guidi ◽  
C. Rossini ◽  
C. Cinelli ◽  
V. Meucci ◽  
I. Lippi
2018 ◽  
Vol 50 (07) ◽  
pp. 556-561 ◽  
Author(s):  
Xiaojing Ma ◽  
Chengyin Zhang ◽  
Hong Su ◽  
Xiaojie Gong ◽  
Xianglei Kong

AbstractWhile obesity is a recognized risk factor for chronic kidney disease, it remains unclear whether change in body mass index (ΔBMI ) is independently associated with decline in renal function (evaluated by the change in estimated glomerular filtration rate, ΔeGFR) over time. Accordingly, to help clarify this we conducted a retrospective study to measure the association of ΔBMI with decline in renal function in Chinese adult population. A total of 4007 adults (aged 45.3±13.7 years, 68.6% male) without chronic kidney disease at baseline were enrolled between 2008 and 2013. Logistic regression models were applied to explore the relationships between baseline BMI and ΔBMI, and rapid decline in renal function (defined as the lowest quartile of ΔeGFR ). During 5 years of follow-up, the ΔBMI and ΔeGFR were 0.47±1.6 (kg/m2) and –3.0±8.8 (ml/min/1.73 m2), respectively. After adjusted for potential confounders, ΔBMI (per 1 kg/m2 increase) was independently associated with the rapid decline in renal function [with a fully adjusted OR of 1.12 (95% CI, 1.05 to 1.20). By contrast, the baseline BMI was not associated with rapid decline in renal function [OR=1.05 (95% CI, 0.98 to 1.13)]. The results were robust among 2948 hypertension-free and diabetes-free participants, the adjusted ORs of ΔBMI and baseline BMI were 1.14 (95% CI, 1.05 to 1.23) and 1.0 (95% CI, 0.96 to 1.04) for rapid decline in renal function, respectively. The study revealed that increasing ΔBMI predicts rapid decline in renal function.


2018 ◽  
Vol 125 (1) ◽  
pp. 31-43 ◽  
Author(s):  
Flávia Sirotheau Corrêa Pontes ◽  
Márcio Ajudarte Lopes ◽  
Lucas Lacerda de Souza ◽  
Diogo dos Santos da Mata Rezende ◽  
Alan Roger Santos-Silva ◽  
...  

2013 ◽  
Vol 4 (9) ◽  
pp. 629
Author(s):  
Milav Bhavsar ◽  
Rita Shah ◽  
Rinku Makadiya ◽  
Jasmin H Jasani ◽  
Sarita Mangukiya

2018 ◽  
Vol 85 (6) ◽  
pp. 755-760 ◽  
Author(s):  
Clotilde Loustau ◽  
Nicolas Rosine ◽  
Marine Forien ◽  
Sébastien Ottaviani ◽  
Pierre-Antoine Juge ◽  
...  

2020 ◽  
Vol 10 (5) ◽  
Author(s):  
Sanam Dolati ◽  
Faezeh Tarighat ◽  
Fariba Pashazadeh ◽  
Kavous Shahsavarinia ◽  
Saina Gholipouri ◽  
...  

: Chronic kidney disease (CKD) is a global public health problem. Pain is one of the most generally experienced symptoms by CKD patients. Pain management is a key clinical activity; nonetheless, insufficient pain management by health professionals keeps it up. Opioids as pain relievers are a class of naturally-derived and synthetic medications. They act through interactions with receptors in peripheral nerves. Numerous pharmacokinetic alterations happen with aging that influence drug disposition, metabolism, and quality of life. Acetaminophen alone, or combined with low-potency opioid dose is regarded as the safest pain-relieving choice for CKD. Morphine and codeine are probably eluded in renal impairment patients and used with excessive carefulness. Tramadol, oxycodone, and hydromorphone can be used by patient monitoring, while methadone, transdermal fentanyl, and buprenorphine seem to be safe to use in older non-dialysis patients with renal impairment. Consistent with the available literature, the main aim of this review was to explore the occurrence of chronic pain and its opioid treatment in CKD patients. According to this review, more and well-made randomized controlled trials are necessary to find appropriate opioid doses and explore the occurrence of side effects.


2020 ◽  
Author(s):  
Anca Pantea Stoian ◽  
Mihaela Pricop-Jeckstadt ◽  
Adrian Pana ◽  
Bogdan-Vasile Ileanu ◽  
Ruxandra Schitea ◽  
...  

Abstract Evidence regarding the relation between SARS-CoV-2 mortality and the underlying medical condition is scarce. We conducted an observational, retrospective study based on Romanian official data about location, age, sex and comorbidities for COVID-19 fatalities. Our findings indicate that males, hypertension, diabetes, obesity and chronic kidney disease were most frequent in the COVID-19 fatalities, that the burden of disease was low, and that the prognosis for 1-year survival probability was high in the sample. Evidence shows that age-dependent pairs of comorbidities could be a negative prognosis factor for the severity of disease for the SARS-CoV 2 infection.


Sign in / Sign up

Export Citation Format

Share Document